{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:11:25Z","timestamp":1790115085801,"version":"4.0.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T00:00:00Z","timestamp":1505779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T00:00:00Z","timestamp":1505779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recently, the <jats:italic>MICA<\/jats:italic> rs2596542 and <jats:italic>DEPDC5<\/jats:italic> rs1012068 variants in Japanese individuals as well as the <jats:italic>HCP5<\/jats:italic> rs2244546 and <jats:italic>PNPLA3<\/jats:italic> rs738409 variants in European individuals have been found associated with hepatocellular carcinoma (HCC). The present study determined which single nucleotide polymorphism (SNP) is the most predictive for developing hepatitis C virus (HCV)-related HCC in a Japanese cohort. Of the 4 SNPs analysed, only the <jats:italic>MICA<\/jats:italic> genotypes were significantly associated with development of HCC (<jats:italic>p<\/jats:italic>\u2009=\u20090.0185). The major (MA), hetero (HE), and minor (MI) genotypes occurred in 40%, 41%, and 19% of HCC patients and in 43%, 47%, and 10% of non-HCC patients, respectively. Interestingly, the <jats:italic>MICA<\/jats:italic> genotype was significantly correlated with <jats:italic>MICA<\/jats:italic> mRNA and soluble protein levels. In patients older than 70 years, the MI genotype was significantly associated with HCC development. In addition, the MI genotype was related to HCC development when the platelet count range was 10\u201315\u2009\u00d7\u200910<jats:sup>4<\/jats:sup>\/\u03bcL, corresponding with the fibrosis stage; but not when the range was less than 10, indicating advanced fibrosis; or greater than 15\u2009\u00d7\u200910<jats:sup>4<\/jats:sup>\/\u03bcL, as mild fibrosis. Thus, polymorphisms in <jats:italic>MICA<\/jats:italic>, but not in <jats:italic>DEPDC5, HCP5<\/jats:italic> or <jats:italic>PNPLA3<\/jats:italic>, are associated with HCC development in Japanese patients with chronic HCV infection.<\/jats:p>","DOI":"10.1038\/s41598-017-10363-5","type":"journal-article","created":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T16:13:05Z","timestamp":1505319185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Polymorphisms in MICA, but not in DEPDC5, HCP5 or PNPLA3, are associated with chronic hepatitis C-related hepatocellular carcinoma"],"prefix":"10.1038","volume":"7","author":[{"given":"Hoang","family":"Hai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le Thi Thanh","family":"Thuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hagihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsushi","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawako","family":"Uchida-Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyasu","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,19]]},"reference":[{"key":"10363_CR1","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/nm.3184","volume":"19","author":"DL Thomas","year":"2013","unstructured":"Thomas, D. L. Global control of hepatitis C: where challenge meets opportunity. Nat Med \n                           19, 850\u2013858 (2013).","journal-title":"Nat Med"},{"key":"10363_CR2","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","volume":"5","author":"CW Shepard","year":"2005","unstructured":"Shepard, C. W., Finelli, L. & Alter, M. J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis \n                           5, 558\u2013567 (2005).","journal-title":"Lancet Infect Dis"},{"key":"10363_CR3","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1002\/ijc.25516","volume":"127","author":"J Ferlay","year":"2010","unstructured":"Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer \n                           127, 2893\u20132917 (2010).","journal-title":"Int J Cancer"},{"key":"10363_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000087257","volume":"49","author":"H Yoshizawa","year":"2006","unstructured":"Yoshizawa, H., Tanaka, J. & Miyakawa, Y. National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population. Intervirology \n                           49, 7\u201317 (2006).","journal-title":"Intervirology"},{"key":"10363_CR5","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1002\/hep.22580","volume":"48","author":"RN Aravalli","year":"2008","unstructured":"Aravalli, R. N., Steer, C. J. & Cressman, E. N. Molecular mechanisms of hepatocellular carcinoma. Hepatology \n                           48, 2047\u20132063 (2008).","journal-title":"Hepatology"},{"key":"10363_CR6","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/ng.876","volume":"43","author":"D Miki","year":"2011","unstructured":"Miki, D. et al. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat Genet \n                           43, 797\u2013800 (2011).","journal-title":"Nat Genet"},{"key":"10363_CR7","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/ng.809","volume":"43","author":"V Kumar","year":"2011","unstructured":"Kumar, V. et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet \n                           43, 455\u2013458 (2011).","journal-title":"Nat Genet"},{"key":"10363_CR8","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jhep.2013.04.032","volume":"59","author":"CM Lange","year":"2013","unstructured":"Lange, C. M. et al. Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma. J Hepatol \n                           59, 504\u2013509 (2013).","journal-title":"J Hepatol"},{"key":"10363_CR9","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/hep.24123","volume":"53","author":"L Valenti","year":"2011","unstructured":"Valenti, L. et al. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology \n                           53, 791\u2013799 (2011).","journal-title":"Hepatology"},{"key":"10363_CR10","doi-asserted-by":"crossref","unstructured":"Corradini, S. G., Burza, M. A., Molinaro, A. & Romeo, S. Patatin-like phospholipase domain containing 3 sequence variant and hepatocellular carcinoma. Hepatology \n                           53, 1776; author reply 1777 (2011).","DOI":"10.1002\/hep.24244"},{"key":"10363_CR11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S1386-6346(98)00075-8","volume":"15","author":"E Ono","year":"1999","unstructured":"Ono, E. et al. Platelet count reflects stage of chronic hepatitis C. Hepatology Research \n                           15, 192\u2013200 (1999).","journal-title":"Hepatology Research"},{"key":"10363_CR12","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s10620-006-9144-y","volume":"52","author":"Z Karasu","year":"2007","unstructured":"Karasu, Z. et al. Liver fibrosis is associated with decreased peripheral platelet count in patients with chronic hepatitis B and C. Dig Dis Sci \n                           52, 1535\u20131539 (2007).","journal-title":"Dig Dis Sci"},{"key":"10363_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1046\/j.1440-1746.2001.02515.x","volume":"16","author":"Y Murawaki","year":"2001","unstructured":"Murawaki, Y., Koda, M., Okamoto, K., Mimura, K. & Kawasaki, H. Diagnostic value of serum type IV collagen test in comparison with platelet count for predicting the fibrotic stage in patients with chronic hepatitis C. J Gastroenterol Hepatol \n                           16, 777\u2013781 (2001).","journal-title":"J Gastroenterol Hepatol"},{"key":"10363_CR14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"D Ge","year":"2009","unstructured":"Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature \n                           461, 399\u2013401 (2009).","journal-title":"Nature"},{"key":"10363_CR15","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nature08463","volume":"461","author":"DL Thomas","year":"2009","unstructured":"Thomas, D. L. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature \n                           461, 798\u2013801 (2009).","journal-title":"Nature"},{"key":"10363_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/jgh.12376","volume":"29","author":"H Hai","year":"2014","unstructured":"Hai, H. et al. Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated-interferon and ribavirin. J Gastroenterol Hepatol \n                           29, 201\u2013207 (2014).","journal-title":"J Gastroenterol Hepatol"},{"key":"10363_CR17","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1002\/hep.26767","volume":"59","author":"E Trepo","year":"2014","unstructured":"Trepo, E. et al. Association between the PNPLA3 (rs738409 C\u2009>\u2009G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. Hepatology \n                           59, 2170\u20132177 (2014).","journal-title":"Hepatology"},{"key":"10363_CR18","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/hep.28322","volume":"63","author":"MA Burza","year":"2016","unstructured":"Burza, M. A. et al. DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection. Hepatology \n                           63, 418\u2013427 (2016).","journal-title":"Hepatology"},{"key":"10363_CR19","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","volume":"40","author":"S Romeo","year":"2008","unstructured":"Romeo, S. et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet \n                           40, 1461\u20131465 (2008).","journal-title":"Nat Genet"},{"key":"10363_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/ng.488","volume":"42","author":"C Tian","year":"2010","unstructured":"Tian, C., Stokowski, R. P., Kershenobich, D., Ballinger, D. G. & Hinds, D. A. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet \n                           42, 21\u201323 (2010).","journal-title":"Nat Genet"},{"key":"10363_CR21","doi-asserted-by":"publisher","first-page":"E137","DOI":"10.1111\/hepr.12258","volume":"44","author":"M Sato","year":"2014","unstructured":"Sato, M. et al. Impact of PNPLA3 polymorphisms on the development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Hepatol Res \n                           44, E137\u2013144 (2014).","journal-title":"Hepatol Res"},{"key":"10363_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/2193-1801-2-251","volume":"2","author":"Y Moritou","year":"2013","unstructured":"Moritou, Y. et al. Predictive impact of polymorphism of PNPLA3 on HCC development after interferon therapy in Japanese patients with chronic hepatitis C. Springerplus \n                           2, 251 (2013).","journal-title":"Springerplus"},{"key":"10363_CR23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jhep.2016.03.011","volume":"65","author":"E Trepo","year":"2016","unstructured":"Trepo, E., Romeo, S., Zucman-Rossi, J. & Nahon, P. PNPLA3 gene in liver diseases. J Hepatol \n                           65, 399\u2013412 (2016).","journal-title":"J Hepatol"},{"key":"10363_CR24","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1111\/j.1478-3231.2011.02534.x","volume":"31","author":"E Falleti","year":"2011","unstructured":"Falleti, E. et al. PNPLA3 rs738409C\/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence. Liver Int \n                           31, 1137\u20131143 (2011).","journal-title":"Liver Int"},{"key":"10363_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027087","volume":"6","author":"HD Nischalke","year":"2011","unstructured":"Nischalke, H. D. et al. The PNPLA3 rs738409 148M\/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. PLoS One \n                           6, e27087 (2011).","journal-title":"PLoS One"},{"key":"10363_CR26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.cgh.2015.08.018","volume":"14","author":"M Ali","year":"2016","unstructured":"Ali, M. et al. A Variant in PNPLA3 Associated With Fibrosis Progression but not Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection. Clin Gastroenterol Hepatol \n                           14, 295\u2013300 (2016).","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10363_CR27","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/nature01112","volume":"419","author":"V Groh","year":"2002","unstructured":"Groh, V., Wu, J., Yee, C. & Spies, T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature \n                           419, 734\u2013738 (2002).","journal-title":"Nature"},{"key":"10363_CR28","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1126\/science.285.5428.727","volume":"285","author":"S Bauer","year":"1999","unstructured":"Bauer, S. et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science \n                           285, 727\u2013729 (1999).","journal-title":"Science"},{"key":"10363_CR29","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/cgt.2015.29","volume":"22","author":"XY Xuan","year":"2015","unstructured":"Xuan, X. Y. et al. Upregulated expression of NKG2D and its ligands give potential therapeutic targets for patients with thymoma. Cancer Gene Ther \n                           22, 368\u2013374 (2015).","journal-title":"Cancer Gene Ther"},{"key":"10363_CR30","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1111\/j.1572-0241.2001.05268.x","volume":"96","author":"A Pohl","year":"2001","unstructured":"Pohl, A. et al. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol \n                           96, 3142\u20133146 (2001).","journal-title":"Am J Gastroenterol"},{"key":"10363_CR31","doi-asserted-by":"crossref","unstructured":"McNamee, R. Regression modelling and other methods to control confounding. Occup Environ Med \n                           62, 500-506, 472 (2005).","DOI":"10.1136\/oem.2002.001115"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-10363-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-10363-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-10363-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T11:10:30Z","timestamp":1671793830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-10363-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,19]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["10363"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-10363-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,19]]},"assertion":[{"value":"5 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Akihiro Tamori has received research funding from MSD K.K., Bristol-Meyers Squibb and Chugai Pharmaceutical Co., Ltd. Norifumi Kawada has received research funding from MSD K.K., Bristol-Meyers Squibb and Chugai Pharmaceutical Co., Ltd. and a lecturer\u2019s fee from Janssen Pharmaceutical K.K. The other authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11912"}}